

Frequency of diabetes and other comorbidities in Chronic Inflammatory Demyelinating Polyradiculoneuropathy and their impact on clinical presentation and response to therapy

Journal:	<i>Journal of Neurology, Neurosurgery, and Psychiatry</i>
Manuscript ID	jnnp-2020-323615.R2
Article Type:	Original research
Date Submitted by the Author:	01-Aug-2020
Complete List of Authors:	<p>Doneddu, Pietro; Istituto Clinico Humanitas - Ospedale a Milano, Neuromuscular and Neuroimmunology Service Cocito, Dario ; Istituti Clinici Scientifici Maugeri - Presidio Sanitario Major, Torino, Italy, Divisione di Riabilitazione Neuromotoria Manganelli, Fiore; University Federico II of Naples, Department of Neurosciences, Reproductive and Odontostomatological Sciences Fazio, Raffaella; San Raffaele Hospital Institute of Experimental Neurology, Department of Neurology Briani, Chiara; University of Padua, Department of Neuroscience Filosto, Massimiliano; ASST 'Spedali Civili', University of Brescia, Unit of Neurology Benedetti, Luana; IRCCS Ospedale Policlinico San Martino Bianchi, Elisa; IRCCS-Istituto Mario Negri, Laboratorio di Malattie Neurologiche Jann, Stefano; Niguarda Ca' Granda Hospital, Department of Neuroscience Mazzeo, Anna; University of Messina, Department of Clinical and Experimental Medicine, Unit of Neurology Antonini, Giovanni; 'Sapienza' University of Rome, Sant' Andrea Hospital, Department of Neurology Mental Health and Sensory Organs (NESMOS) Cosentino, Giuseppe; University of Pavia, IRCCS Mondino Foundation Marfia, Girolama; Univeristy of Roma Tor Vergata, Department of Systems Medicine Cortese, Andrea; University of Pavia. IRCCS Mondino Foundation Clerici, Angelo; Insubria University , Neurology Unit, Circolo & Macchi Foundation Hospital Carpo, Marinella; ASST Bergamo Ovest-Ospedale Treviglio Schenone, Angelo; University of Genoa and IRCCS AOU San Martino-IST, Department of Neuroscience, Rehabilitation, Ophtalmology, Genetics, Maternal and Child Health Siciliano, Gabriel; University of Pisa, Neurology Unit, Department of Clinical and Experimental Medicine Luigetti, Marco; Fondazione Policlinico Universitario Agostino Gemelli IRCCS, UOC Neurologia; Universita Cattolica del Sacro Cuore Sede di Roma Lauria, Giuseppe; Foundation IRCCS Carlo Besta Neurological Institute, Unit of Neuroalgology; University of Milan, Department of Biomedical and</p>

1	
2	
3	
4	Clinical Sciences 'Luigi Sacco'
5	Rosso, Tiziana; ULSS2 Marca Trevigiana, UOC Neurologia-Castelfranco Veneto
6	Cavaletti, Guido; Università degli Studi di Milano-Bicocca, School of
7	Medicine and Surgery and Experimental Neurology Unit
8	Beghi, Ettore; IRCCS Mario Negri, Laboratorio di Malattie Neurologiche
9	Liberatore, Giuseppe; Humanitas Clinical and Research Institute,
10	Neuromuscular and Neuroimmunology Service
11	Santoro, Lucio; University of Naples Federico II School of Medicine and
12	Surgery, Department of Neuroscience, Reproductive Sciences and
13	Odontostomatology
14	Spina, Emanuele; University of Naples Federico II School of Medicine and
15	Surgery, Department of Neuroscience, Reproductive Sciences and
16	Odontostomatology
17	Peci, Erdita; University of Turin, Department of Neuroscience
18	Tronci, Stefano; San Raffaele Hospital Institute of Experimental
19	Neurology, Division of Neuroscience, Department of Neurology
20	Ruiz, Marta; University of Padua, Neurology Unit, Department of
21	Neuroscience
22	Cotti Piccinelli, Stefano; ASST 'Spedali Civili', University of Brescia,
23	Center for Neuromuscular Diseases and Neuropathies, Unit of Neurology
24	Verrengia, Elena; Niguarda Ca' Granda Hospital, Department of
25	Neuroscience
26	Gentile, Luca; Università degli Studi di Messina, Department of Clinical
27	and Experimental Medicine, Unit of Neurology
28	Leonardi, Luca; Sapienza University of Rome, Neurology Mental Health
29	and Sensory Organs (NESMOS)
30	Mataluni, Giorgia; Università degli Studi di Roma Tor Vergata,
31	Department of Systems Medicine
32	Piccolo, Laura; Università degli Studi di Pavia, IRCCS Mondino
33	Foundation
34	Nobile-Orazio, Eduardo; University of Milan, Department of Medical
35	Biotechnology and Translational Medicine; Istituto Clinico Humanitas -
36	Ospedale a Milano, Neuromuscular and Neuroimmunology Service
37	
38	
39	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49	
50	
51	
52	
53	
54	
55	
56	
57	
58	
59	
60	

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3 **Frequency of diabetes and other comorbidities in Chronic Inflammatory**
4
5
6 **Demyelinating Polyradiculoneuropathy and their impact on clinical presentation**
7
8
9 **and response to therapy**
10

11
12 Pietro E. Doneddu¹, Dario Cocito², Fiore Manganelli³, Raffaella Fazio⁴, Chiara Briani⁵,
13
14 Massimiliano Filosto⁶, Luana Benedetti⁷, Elisa Bianchi⁸, Stefano Jann⁹, Anna Mazzeo¹⁰, Giovanni
15
16 Antonini¹¹, Giuseppe Cosentino¹², Girolama A. Marfia¹³, Andrea Cortese¹², Angelo M. Clerici¹⁴,
17
18 Marinella Carpo¹⁵, Angelo Schenone¹⁶, Gabriele Siciliano¹⁷, Marco Luigetti^{18,19}, Giuseppe
19
20 Lauria^{20,21}, Tiziana Rosso²², Guido Cavaletti²³, Ettore Beghi⁸, Giuseppe Liberatore¹, Lucio Santoro³,
21
22 Emanuele Spina³, Erdita Peci², Stefano Tronci⁴, Marta Ruiz⁵, Stefano Cotti Piccinelli⁶, Elena
23
24 Pinuccia Verrengia⁹, Luca Gentile¹⁰, Luca Leonardi¹¹, Giorgia Mataluni¹³, Laura Piccolo¹², Eduardo
25
26 Nobile-Orazio^{1,24}, on the behalf of the Italian CIDP Database Study Group.
27
28
29

- 30
31
32 1. Neuromuscular and Neuroimmunology Service, IRCCS Humanitas Clinical and Research
33 Institute, Rozzano, Milan, Italy
34
35 2. Department of Neuroscience, University of Turin, Turin, Italy
36
37 3. Department of Neuroscience, Reproductive Sciences and Odontostomatology, University of
38 Naples 'Federico II', Naples, Italy
39
40 4. Division of Neuroscience, Department of Neurology, Institute of Experimental Neurology
41 (INSPE), San Raffaele Scientific Institute, Milan, Italy
42
43 5. Neurology Unit, Department of Neuroscience, University of Padua, Padua, Italy
44
45 6. Center for Neuromuscular Diseases and Neuropathies, Unit of Neurology, ASST 'Spedali
46 Civili', University of Brescia, Brescia, Italy
47
48 7. IRCCS Ospedale Policlinico San Martino Genova
49
50 8. Laboratorio di Malattie Neurologiche, IRCCS-Istituto Mario Negri, Milan, Italy
51
52 9. Department of Neuroscience, Niguarda Ca' Granda Hospital, Milan, Italy
53
54 10. Department of Clinical and Experimental Medicine, Unit of Neurology, University of
55 Messina, Messina, Italy
56
57 11. Unit of Neuromuscular Diseases, Department of Neurology Mental Health and Sensory
58 Organs (NESMOS), Faculty of Medicine and Psychology, 'Sapienza' University of Rome,
59 Sant'Andrea Hospital, Rome, Italy
60
12. University of Pavia, Pavia, Italy. IRCCS Mondino Foundation, Pavia, Italy

- 1 13. Dysimmune Neuropathies Unit, Department of Systems Medicine, Tor Vergata University
2 of Rome, Rome, Italy
- 3
- 4 14. Neurology Unit, Circolo & Macchi Foundation Hospital, Insubria University, DBSV,
5 Varese, Italy
- 6
- 7 15. ASST Bergamo Ovest-Ospedale Treviglio, Treviglio, Italy
- 8
- 9 16. Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child
10 Health, University of Genoa and IRCCS AOU San Martino-IST, Genoa, Italy
- 11
- 12 17. Neurology Unit, Department of Clinical and Experimental Medicine, University of Pisa,
13 Pisa, Italy
- 14
- 15 18. Fondazione Policlinico Universitario Agostino Gemelli IRCCS. UOC Neurologia
- 16
- 17 19. Università Cattolica del Sacro Cuore. Sede di Roma
- 18
- 19 20. Unit of Neuroalgology, IRCCS Foundation 'Carlo Besta' Neurological Institute, Milan, Italy
- 20
- 21 21. Department of Biomedical and Clinical Sciences 'Luigi Sacco', University of Milan, Milan,
22 Italy
- 23
- 24 22. ULSS2 Marca Trevigiana, UOC Neurologia-Castelfranco Veneto, Treviso, Italy
- 25
- 26 23. School of Medicine and Surgery and Experimental Neurology Unit, University of Milano-
27 Bicocca, Monza, Italy
- 28
- 29 24. Department of Medical Biotechnology and Translational Medicine, Milan University,
30 Milan, Italy
- 31
- 32
- 33
- 34

35 *Address Correspondence to: Eduardo Nobile-Orazio, MD, PhD, FAAN, Department of Medical*
36 *Biotechnology and Translational Medicine (BIOMETRA), Milan University, 2nd Neurology, IRCCS*
37 *Humanitas Research Hospital, Via Manzoni 56, Rozzano, Milan 20089, Italy. Tel:*
38 *+390282242209; Fax: +390282242298; E-mail: eduardo.nobile@unimi.it.*
39

40
41
42 Word count: 3630 words

43
44 Number of references: 46
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT

Objectives to determine the prevalence of different comorbidities in Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP), and their impact on outcome, treatment choice and response.

Methods using a structured questionnaire we collected information on comorbidities from 393 CIDP patients fulfilling the EFNS/PNS criteria included in the Italian CIDP database.

Results one or more co-morbidities were reported by 294 patients (75%) and potentially influenced treatment choice in 192 (49%) leading to a less frequent use of corticosteroids. Response to treatment did not differ however from that in patients without comorbidities. Diabetes (14%), MGUS (12%) and other immune disorders (16%) were significantly more frequent in CIDP patients than expected in the general European population. Patients with diabetes had higher disability scores, worse quality of life (QoL), and a less frequent treatment response compared to patients without diabetes. Patients with IgG-IgA or IgM MGUS had an older age at CIDP onset while patients with other immune disorders had a younger age at onset and were more frequently females. IgM MGUS was more frequent in patients with motor CIDP than in patients with typical CIDP.

Conclusions comorbidities are frequent in patients with CIDP and in almost 50% of them have an impact on treatment choice. Diabetes, MGUS and other immune diseases are more frequent in patients with CIDP than in the general population. Only diabetes seems however to have an impact on disease severity and treatment response possibly reflecting in some patients a co-existing diabetic neuropathy.

Keywords: Chronic inflammatory demyelinating polyneuropathy; Diabetes mellitus; monoclonal gammopathy of undetermined significance; comorbidities; lymphoma

INTRODUCTION

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a chronic disabling neuropathy, postulated to have an immune-mediated basis.[1] A number of concomitant disorders have been reported to occur in patients with CIDP[1] including diabetes mellitus (DM),[2-6] lymphoma,[7-9] solid cancer,[9] monoclonal gammopathy of undetermined significance (MGUS),[10-13] plasma cell dyscrasias,[9,14] and other disorders.[15-18] Most of these associations have been reported in isolated cases or small series of patients so that their frequency in CIDP and possible clinical and pathogenic relevance, impact on disability, quality of life (QoL), and response to treatment remains unclear. There are also conflicting data on the association and clinical impact of DM in CIDP. The frequency of DM has been reported to be increased in some series of CIDP patients[2,5] but not in others[3,4] with a variable effect on the response to treatment, leading to the exclusion of these patients from some clinical trials on CIDP. Some of these comorbidities may also theoretically interfere with the pathogenesis, clinical presentation, accumulation of disability, and treatment response of CIDP by causing additional axonal damage or a perturbation of the immune homeostasis. We collected data on comorbidities from a large cohort of patients with CIDP to determine (1) the prevalence of comorbidities in CIDP, (2) their impact on treatment choice (3) outcome and response to treatment, and (4) association with a specific clinical phenotype of CIDP.

PATIENTS AND METHODS

Study design

We implemented a web-based database on Italian CIDP patients where data from 435 patients with CIDP diagnosed according to the European Federation of Neurological Societies and Peripheral Nerve Society (EFNS/PNS) criteria were included.[1] At enrolment, all eligible patients underwent a detailed clinical history including timing and distribution of neurological signs, a number of

1 disability scales, and a neurophysiological study. We used the same methodology as the one
2 employed in a previous study.[19] We also collected information on the presence and duration of
3 concurrent medical illnesses.[20] These were classified as: bone marrow transplantation, DM, HIV
4 infection, chronic active hepatitis, IgG or IgA MGUS, IgM MGUS including those with low titers
5 of anti-MAG (myelin-associated glycoprotein) antibodies (defined in laboratory as less than 7000
6 [BTU] Bühlmann Titer Unit), other hematological diseases, systemic lupus erythematosus or other
7 connective tissue diseases, lymphoma, sarcoidosis, vasculitis, other immune mediated diseases,
8 thyroid diseases, solid neoplasms, glomerulonephritis, nephropathy, thrombosis, cardiovascular
9 diseases, arterial hypertension, gastrointestinal diseases, others conditions. Duration of each
10 comorbidity was considered from the time when the patients first developed symptoms or, in case
11 of paucisymptomatic diseases such as arterial hypertension, from the time they were diagnosed as
12 having that specific comorbidity by their physician. Information on comorbidities was retrieved by
13 demographic and clinical data from medical charts and by a detailed clinical history with the
14 individual patient using a structured questionnaire.

15 All the data were included by the treating neurologist in a web-based electronic database expressly
16 prepared by CINECA, Bologna, Italy. The diagnosis of CIDP was made by the treating neurologist
17 and reviewed by the coordinating Centre (P.E.D. and E.N.O.) and classified according to the
18 EFNS/PNS diagnostic criteria.[1] Informed consent was obtained from all participants at
19 enrollment, and the Ethical Committee of each participating Center approved the study.

20 *Prevalence of different comorbidities in CIDP and their impact on treatment choice*

21 The prevalence (as percentage of the total) of each individual comorbidity and of combined
22 comorbidity groups (e.g. cardiovascular diseases including chronic heart failure, coronary heart
23 disease, valvular heart disease, etc) was calculated. The prevalence of comorbidities potentially
24 affecting treatment choice was also assessed. These comorbidities were defined as those known to
25 be associated with an increased risk of side effects after steroids, intravenous immunoglobulin
26 (IVIg), or plasma exchange (PEX) therapy, including arterial hypertension, DM, gastrointestinal
27 diseases, cardiovascular diseases, thrombosis, nephropathy, glomerulonephritis, and chronic active
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 hepatitis. Given the small number of patients treated with immune suppressants in our database, the
2
3 analysis did not include these therapies.
4

5 Given the observed elevated frequency of DM and MGUS in our CIDP patients, we compared the
6
7 data with the estimated age- and gender-specific prevalence rates of DM and of MGUS in
8
9 Italy.[21,22] The expected number of patients with MGUS was also determined using the general
10
11 population of a community in Minnesota as reference.[23] We excluded patients younger than 50
12
13 years from the comparison with the study by Kyle *et al* and younger than 51 years from that by
14
15 Vernocchi *et al* since these patients were not included in these studies.[22,23] We also evaluated
16
17 fulfillment of the recently proposed diagnostic criteria of CIDP in patients with DM.[24]
18
19

20 21 *Role of comorbidities in the clinical presentation, disability and treatment response of CIDP*

22
23 We evaluated the impact of comorbidities on the clinical presentation, outcome, and treatment
24
25 response of CIDP by comparing patients with and without these comorbidities. The comparison was
26
27 performed only for comorbidities with a number of patients sufficient for statistical analysis. We
28
29 also looked for differences in the frequency of comorbidities between patients with typical and
30
31 atypical CIDP and evaluated their association with progression from atypical to typical CIDP.
32
33 Atypical CIDP was defined as pure motor or sensory CIDP, distal acquired demyelinating
34
35 symmetric polyneuropathy (DADS), and Lewis-Sumner syndrome (LSS).[19] Response to
36
37 treatment was defined as a subjective improvement that was objectively confirmed by an increase of
38
39 at least 2 points in the MRC sum score (range 0-60)[25,26] or at least 1 point in the INCAT score
40
41 (range 0-10).
42
43
44
45
46
47

48 **Statistical analysis**

49
50 Descriptive statistics were reported as frequencies and percentages for categorical variables, or as
51
52 means, medians and ranges for continuous variables. To determine if the prevalence of DM and
53
54 MGUS in CIDP patients differs from the prevalence in the general population, the observed
55
56 prevalence was compared to the expected prevalence calculating age- and gender-standardized
57
58 prevalence ratios (SPR), with 95% confidence intervals. Age and gender-specific prevalence from
59
60

1 the reference population was used to estimate the number of expected cases of DM and MGUS in
2 each age and sex category. SPR were then calculated as the ratio between the observed and
3 expected number of cases. Demographic and clinical features, treatment response, impairment,
4 disability level and quality of life were compared between different subgroups of patients with the
5 chi-square or the Fisher's exact test for categorical variables, and with the t-test for continuous
6 variables. The effect of each comorbidity on disability and quality of life was assessed using linear
7 regression models, adjusting for disease duration. The effect of each comorbidity on treatment
8 response was evaluated using logistic regression models, adjusting for disease duration. All tests
9 were two-tailed and the significance level was set to 0.05.

21 RESULTS

22 By October 2019, 435 patients with CIDP fulfilling the EFNS/PNS criteria were enrolled in our
23 database including 428 with definite or probable CIDP. Twenty-four patients were excluded from
24 the analysis for the presence of an alternative diagnosis (19 patients with anti-MAG titers over 7000
25 BTU, one with Charcot-Marie Tooth 1A, three with amyloidosis, and one with only cranial nerve
26 palsy) and 21 patients for unavailable neurophysiological data. A total 393 patients (252 men and
27 141 women, aged 11-92 years [mean 58; median 60 years], mean disease duration of 8.2 years
28 [range 0.5-52 years, median 5 years]), had complete data on comorbidities and were included in the
29 analysis.

42 Frequency of comorbidities in CIDP and their impact on treatment choice

43 Table 1 shows the frequency and percentage of different comorbidities in our cohort of patients
44 with CIDP. These are also grouped as comorbidity combinations in figure 1. Seventy-five per cent
45 (n. 294) of patients reported at least one comorbidity, and 54% (214 patients) two or more
46 comorbidities. Diabetes (14%), MGUS (12%) and other immune disorders (16%) were significantly
47 more frequent in CIDP patients than expected in the general European population (see below).
48 Arterial hypertension (35%), cardiovascular diseases (11%), thyroid diseases (11%) and solid
49 neoplasms (9%) were also frequent in our population but their prevalence did not significantly
50 differ from what reported in the Italian population.[27,28]

Table 1. Frequency distribution of comorbidities in 393 patients with CIDP

Comorbidities	Number of patients; Frequency (%)
Arterial hypertension	138 (35%)
Other immune diseases	61 (15%)
a) Autoimmune thyroiditis; b) Rheumatic immune diseases; c) Gastrointestinal immune diseases; d) Dermatologic immune diseases e) Neurological immune diseases f) Miscellany	a) 22 (5%); b) 13 (3.5%); c) 9 (2%); d) 6 (1.5%); e) 5 (1.5%); f) 6 (1.5%)
Diabetes mellitus	56 (14%)
Cardiovascular diseases	45 (11%)
a) Coronary disease; b) Arrhythmia; c) Stroke; d) Valvular heart disease	a) 31 (8%); b) 9 (2%); c) 3 (1%); d) 2 (0.5%)
Thyroid diseases	42 (11%)
a) Hypothyroidism; b) Thyroid nodules; c) Goiter; d) Hyperthyroidism; e) NS	a) 13 (3%); b) 8 (2%); c) 4 (1%); d) 2; e) 7 (2%)
Solid neoplasm	35 (9%)
a) Urological cancer; b) Gastrointestinal cancer; c) Head and Neck cancer; d) Breast cancer; e) Others	a) 11 (3%); b) 5 (1.5%); c) 4 (1%); d) 4 (1%); e) 11 (3%)
IgG-IgA MGUS	25 (6%)
IgM MGUS	24 (6%)
Other hematological disorders	21 (5%)
a) Polycythemia vera; b) Thalassemia minor; c) Anemia; d) Thrombocytopenia; e) Others	a) 4 (1%); b) 2; c) 2; d) 2; e) 11 (2.5%)
Gastrointestinal diseases	21 (5%)
a) GERD and gastritis; b) Hepatic and pancreatic disorders; c) Peptic ulcer disease; d) Others	a) 9 (2%); b) 3 (1%); c) 3 (1%); d) 5 (1.5%)
Thrombosis	11 (3%)
Nephropathy	8 (2%)
a) Renal insufficiency; b) Others	a) 6 (2%); b) 2
Chronic active hepatitis	7 (2%)

1	a) HBV infection; b) NS	a) 6 (1.5%); b) 1
2		
3	Lymphoma	7 (2%)
4		
5	Bone marrow transplantation	5 (1.5%)
6		
7		
8	Glomerulonephritis	3 (1%)
9		
10	Others	66 (17%)
11		
12		
13	a) Miscellany; b) Other Neurologic/Psychiatric disorders; c) Metabolic disorders;	a) 16 (4%); b) 13 (3%); c) 13 (3%);
14		
15	d) Urologic disorders; e) Respiratory disorders; f) Skeletal disorders	d) 10 (2.5%); e) 7 (2%); f) 7 (2%)
16		
17	HIV infection	0
18		
19		

20 GERD= gastroesophageal reflux disease; MGUS= monoclonal gammopathy of undetermined significance; NS= not
 21 specified;

22
 23
 24
 25 One or more comorbidities potentially influencing the choice of treatment were present in 192
 26 (49%) patients (figure 2), and two or more comorbidities in 77 (19.5%) patients. Corticosteroids
 27 were used less frequently in these patients compared to those without these comorbidities (49% vs
 28 61%; $p= 0.0199$). There was no difference between the two groups in terms of use of IVIg (74% vs
 29 79%; $p= 0.3407$) and PEx (11% vs 9%; $p= 0.6001$), number of not treated patients (7% vs 8%; $p=$
 30 0.7044), number of treatments performed (mean 1.9 vs 1.9; $p= 0.5139$), and response to treatment
 31 (85% vs 87%; $p= 0.6445$).

42 CIDP and Diabetes

43
 44
 45 Fifty-six out of our 393 (14%) patients with CIDP had DM. This percentage is higher than expected
 46 in the general Italian population (8.6%). Information about type of DM (1 or 2) was not however
 47 systematically collected in our database. The corresponding SPR was 1.66 (95% CI, 1.31–2.07),
 48 indicating that the frequency of DM was significantly higher than expected in the general
 49 population (supplementary table 1). An increased risk of DM was found in both sexes and younger
 50 patients (< 55 years) showed the greatest risk increase. Mean score of the recently proposed
 51 diagnostic criteria for CIDP in DM[24] among our patients was 12 (median 12; mode 12; range 1-
 52
 53
 54
 55
 56
 57
 58
 59
 60

18; SD \pm 3.6; reported reference score: \geq 11 points = definite, 5-10 points = probable, 2-4 points = possible, $<$ 2 points = unlikely), with only one patient with a score below 2 points, 11 patients with a score of 5-10 points, and 44 patients with a score of at least 11 points. The patient with a score of 1 point had a sensorimotor DADS with reduced motor conduction velocity in three nerves improved after IVIg therapy.

CIDP and MGUS

Forty-nine (12%) CIDP patients had MGUS, including 25 (6%) with IgG or IgA MGUS and 24 (6%) with IgM MGUS. These figures were significantly higher compared to the American sample, in all age decade with the exception of patients above 80 years (supplementary table 2). An increased risk of MGUS was also found in comparison with the Italian sample (supplementary table 3) apart from the age ranges 51-60 and 81-90, even if in the former decade the frequency was double than in the Italian general population.

CIDP and other immune diseases

Sixty-one (15%) of our CIDP patients had another immune disorders (excluding DM). This figure was more than three times higher compared to the estimated prevalence of immune diseases in the general population in Europe[29] and is similar to what observed in other immune diseases where an increased risk of other immune diseases was also reported.

Role of comorbidities on the clinical presentation, disability and treatment response

Compared to CIDP patients without DM, patients with CIDP and DM had an older age at symptoms onset, more frequent signs of autonomic impairment, increased CSF proteins levels, higher disability by RODS and INCAT, and a worse QoL (table 2). They also had a less frequent response to treatment compared to patients without DM. There was not, however, a significant difference in the response to IVIg or steroids. Patients with CIDP and IgG-IgA MGUS had an older age at symptoms onset and a more frequent cranial nerve involvement compared to those without IgG-IgA MGUS. An older age at CIDP symptoms onset was also found in patients with IgM MGUS and in

1 patients with a medical history of solid neoplasm. Patients with CIDP and other immune disorders
2
3 had a younger age at symptoms onset, more frequently were females, had a longer disease duration,
4
5 and a more frequent cranial nerve involvement compared to those without other immune disorders.
6
7
8 No other differences were found among groups.
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Confidential: For Review Only

Table 2. Role of comorbidities in the clinical presentation, disability and treatment response of CIDP

	Diabetes (n. 56)	Without Diabetes (n. 337)	IgG-IgA MGUS (n. 25)	Without IgG-IgA MGUS (n. 368)	IgM MGUS (n. 24)	Without IgM MGUS (n. 369)	Lymphoma (n. 7)	Without lymphoma (n. 386)	Solid neoplasm (n. 35)	Without solid neoplasm (n. 358)	Other immune diseases (n. 61)	Without other immune diseases (n. 332)
Time (years) from CIDP to index comorbidity; mean (range)	8 (1-29)		6.5 (1-44)		4 (1-16)		18 (8-39)		8.5 (1-21)		16 (1-34)	
Time (years) from index comorbidity to CIDP; mean (range)	10 (1-29)		8 (1-17)		5 (1-10)		8 (7-10)		10 (1-25)		11 (1-37)	
Gender (M:F)	42:14	210:127	17:8	235:133	13:11	239:130	3:4	249:137	23:12	229:129	28:33*	224:108
Age at onset; years; mean (range)	54 (14-85)*	49 (6-86)	59.5 (24-86)**	49 (6-85)	56.5 (24-75)*	49 (6-86)	50 (15-67)	50 (6-86)	57 (10-82)**	49 (6-86)	43 (9-80)**	51 (6-86)
Disease duration; years; mean (range)	8.5 (0.5-31)	8 (0.5-52)	7 (0.5-45)	8 (0.5-52)	9 (0.5-33)	8 (0.5-52)	14 (2-46)	8 (0.5-52)	6.5 (0.5-32)	8 (0.5-52)	11 (0.5-52)*	8 (0.5-46)
Fatigue	31 (55%)	182 (54%)	11 (44%)	202 (55%)	13 (54%)	200 (54%)	2 (28.5%)	211 (55%)	18 (51%)	195 (54%)	33 (54%)	180 (54%)
Pain	21 (37.5%)	102 (30%)	7 (28%)	116 (31.5%)	8 (33%)	115 (31%)	3 (43%)	120 (31%)	6 (17%)	117 (33%)	24 (39%)	99 (30%)
Cranial nerve involvement	9 (16%)	74 (22%)	11 (44%)**	72 (19.5%)	2 (8%)	81 (22%)	0	83 (21.5%)	7 (20%)	76 (21%)	20 (33%)*	63 (19%)
Ataxia	22 (39%)	96 (28%)	10 (40%)	108 (29%)	7 (29%)	111 (30%)	4 (57%)	114 (29.5%)	10 (28.5%)	108 (30%)	19 (31%)	99 (30%)
Tremor	10 (18%)	37 (11%)	3 (12%)	44 (12%)	5 (21%)	42 (11%)	2 (28.5%)	45 (12%)	6 (17%)	41 (11%)	10 (16%)	37 (11%)
Dysautonomia	8 (14%)*	19 (5%)	3 (12%)	24 (6%)	2 (8%)	25 (7%)	1 (14%)	26 (7%)	4 (11%)	23 (6%)	7 (11%)	20 (6%)
Increased CSF proteins; positive/tested	39/41 (95%)*	206/256 (80%)	18/20 (90%)	225/277 (81%)	15/21 (71%)	229/276 (83%)	6/6 (100%)	238/291 (82%)	24/27 (89%)	220/269 (82%)	37/44 (84%)	207/252 (82%)
Mean CSF proteins; mg/dL (range)	127 (45-540)	121 (45-1000)	120 (45-540)	122 (45-1000)	135 (45-540)	120 (45-1000)	141 (59-240)	121 (45-1000)	139 (45-1000)	118 (45-679)	152 (45-1000)	116 (45-679)
Nerve imaging; positive/tested	4/6 (67%)	37/45 (82%)	3/3 (100%)	38/48 (79%)	2/3 (67%)	39/48 (81%)	0	41/51 (80%)	4/6 (67%)	37/45 (82%)	6/6 (100%)	35/45 (78%)

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

Nerve biopsy; positive/tested	4/6 (67%)	16/28 (57%)	0/0	19/33 (57.5%)	1/1 (100%)	19/32 (59%)	0	20/33 (61%)	1/3 (33%)	19/30 (63%)	5/6 (83%)	15/27 (55%)
MRC sum score; least squares mean (std. err.) ¹	52.7 (0.9)	54.6 (0.4)	55.7 (1.4)	54.2 (0.4)	53.5 (1.4)	54.4 (0.4)	54.7 (2.6)	54.3 (0.3)	54.0 (1.1)	54.3 (0.4)	54.6 (0.9)	54.3 (0.4)
I-RODS score; least squares mean (std. err.) ¹	28.1 (1.6)**	33.4 (0.6)	32.6 (2.5)	32.7 (0.6)	28.5 (2.5)	33.0 (0.6)	25.6 (5.4)	32.8 (0.6)	36.2 (2.1)	32.4 (0.6)	32.5 (1.5)	32.8 (0.6)
INCAT disability score; least squares mean (std. err.) ¹	3.3 (0.3)**	2.5 (0.1)	2.3 (0.4)	2.7 (0.1)	3.4 (0.4)	2.6 (0.1)	3.0 (0.8)	2.6 (0.1)	2.7 (0.3)	2.6 (0.1)	2.7 (0.3)	2.6 (0.1)
Quality of life score; least squares mean (std. err.) ¹	8.9 (0.3)**	7.9 (0.1)	8 (0.5)	8 (0.1)	8.2 (0.5)	8.0 (0.1)	9.4 (1.0)	8.0 (0.1)	7.6 (0.4)	8.0 (0.1)	8 (5-12)	8 (1-14)
Treatment response	36/51 (71%)**	266/304 (88%)	17/21 (81%)	285/334 (85%)	18/23 (78%)	284/332 (86%)	4/5 (80%)	298/350 (85%)	27/31 (87%)	275/324 (85%)	51/57 (89%)	251/298 (84%)
Corticosteroids	11/20 (55%)	101/200 (51%)	9/15 (60%)	103/205 (50%)	7/17 (41%)	105/203 (52%)	1/3 (33%)	111/217 (51%)	13/23 (57%)	99/197 (50%)	23/39 (59%)	89/181 (59%)
Intravenous immunoglobulin	29/44 (66%)	190/258 (74%)	13/17 (76%)	206/285 (72%)	12/19 (63%)	207/283 (73%)	3/5 (60%)	216/297 (73%)	19/27 (70%)	200/275 (73%)	33/48 (69%)	186/254 (73%)

CSF= cerebrospinal fluid; F= females; M= males; MGUS= monoclonal gammopathy of undetermined significance; MRC= Medical Research Council

*p<0.05; **p<0.01; least square means obtained from a linear model adjusted for disease duration;

¹ std. err.=standard error.

1 There was no significant difference in the distribution of comorbidities among the different CIDP
2 phenotypes with the only exception of a more frequent IgM MGUS in patients with pure motor
3 CIDP compared to patients with typical CIDP (23% vs 5.5%, $p=0.0393$). There was no significant
4 difference in the prevalence of comorbidities between patients with atypical CIDP progressed or not
5 to typical CIDP.
6
7
8
9
10

11 **DISCUSSION**

12
13 In this study, 75% of the patients with CIDP had at least one comorbidity and about half of them at
14 least two comorbidities. These figures are higher than those reported by other studies, where the
15 observed frequency of comorbidities ranged from 25% to 43%,[13,30,31] possibly reflecting the
16 larger number of patients in our cohort, differences in age distribution, or in the methods of
17 ascertainment. Most importantly, about half of the patients had one or more comorbidities that
18 potentially influenced the choice of treatment. Although in these patients steroid therapy was less
19 frequently used to avoid the increased risk of side effects,[6] the overall response to treatment was
20 similar to that of patients without these comorbidities. Our data indicate that the recommendation of
21 the EFNS/PNS on basing the choice of therapy on the presence of relative contraindications to
22 individual therapy [1], probably applies to a much larger population of CIDP patients than currently
23 presumed.
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40

41
42 DM was significantly more frequent in our patients with CIDP compared to what expected from a
43 representative sample of the Italian population.[21] The increased risk of DM was present in both
44 sexes, and mostly involved younger age groups even if the mean age of patients with DM was older
45 than that of patients without. Conflicting data emerge from previous studies on the association of
46 CIDP with DM.[2-6] It might be difficult in some patients to establish whether a neuropathy with
47 some electrodiagnostic features consistent with demyelination is caused by DM itself or by
48 CIDP.[5,6,32] It is well known that a certain degree of motor conduction slowing may be seen in
49 diabetic neuropathy.[6] Compared to previous studies, most of which are population-based and
50 possibly used less stringent inclusion and exclusion criteria, in all our patients the diagnosis of
51
52
53
54
55
56
57
58
59
60

CIDP was made by neurologists expert in peripheral neuropathies and all the patients with DM fulfilled the EFNS/PNS diagnostic criteria for probable or definite CIDP.[1] In addition, the increased prevalence of DM in CIDP in our population was confirmed using the recently proposed diagnostic criteria for CIDP in DM.[24] Although these criteria have not yet been validated, the parameters taken into consideration were reported to allow a distinction between CIDP and diabetic polyneuropathy.[5,6] Apart from two patients with LSS and one patient with DADS, all our patients with DM had a non-length dependent sensory-motor neuropathy that was clinically distinguishable from diabetic neuropathy. The more frequent occurrence of dysautonomia in patients with DM may however reflect that in some patients DM might have influenced the neuropathy as possibly confirmed by the higher levels of disability and worse QoL in DM than non-DM patients, suggesting a possible coexistence of diabetic neuropathy and CIDP in some patients. Similar conclusion may also derive from the less frequent response to therapy in these patients compared to those without DM, even if this was not associated with a different response to IVIg or steroids. This discrepancy may explain the previously reported conflicting results on the response to therapy in CIDP patients with DM in small series of patient, even if most of them reported a similar response in patients with DM.[5,6,32-35] The reasons for the possible association of CIDP with DM remains however unclear. Putative pathogenic mechanisms underlying the link between CIDP and DM may include an increased activation of proinflammatory cytokines and matrix metalloproteinase-9 in the peripheral nerves,[33] or exposure to the immune system of nerve antigen released by diabetes induce nerve damage, as possibly indicated by the reported presence of low levels of antibodies against phospholipid, gangliosides and sulfatide in diabetic neuropathy.[34]

We confirmed the high prevalence of MGUS (IgG, IgA or IgM MGUS) (12%) in our cohort of CIDP patients. This figure is four-fold higher than that found in an American sample,[23] and almost twice that found in an Italian sample[22] where the more sensitive capillary electrophoresis was used. Our results are in line with a previous population study in Olmsted county, reporting an increased risk of CIDP in persons with MGUS (relative risk: 5.9; 95% CI 1.2–28.4),[36] and with studies on small groups of patients reporting an increased frequency (range 17-36%) of MGUS in

1 patients with CIDP.[10-13,30,37] We also confirmed the increased prevalence of IgM than IgG
2
3 MGUS in our CIDP patients (1:1)[10-13,37] compared to what observed in the general population
4
5 (about 1:4).[23] IgM MGUS is known to be more frequently associated with peripheral neuropathy
6
7 compared to IgG or IgA MGUS but so far only anti-MAG antibody specificity has shown a clear
8
9 relationship with a specific clinical phenotype.[38] All our patients with IgM MGUS did not have
10
11 however anti-MAG antibodies. Only three of the 24 patients with IgM MGUS had the DADS
12
13 phenotype currently associated with anti-MAG antibodies, while most of them had the typical CIDP
14
15 phenotype. IgM MGUS was more frequent in patients with pure motor CIDP compared to patients
16
17 with typical CIDP. Two of the three patients with pure motor CIDP and IgM MGUS had high anti-
18
19 GM1 antibodies (1:2400 and 1:80.000). Both patients had symmetric weakness at the four limbs
20
21 and one also reduced sensory nerve conduction velocities making it unlikely a misdiagnosis with
22
23 multifocal motor neuropathy (MMN). The presence of anti-GM1 IgM antibodies was also reported
24
25 by Busby and Donaghy in two of seven patients with pure motor CIDP compared to none of 25
26
27 patients with typical CIDP.[37] If confirmed, the increased frequency of anti-GM1 antibodies in
28
29 patients with pure motor CIDP may reinforce the hypothesis raised by the reported deterioration of
30
31 these patients under steroid therapy[1] that these patients may have a symmetric form of MMN
32
33 instead of a purely motor CIDP. It is also possible that patients with IgM MGUS have antibodies
34
35 against other identified (such as GQ1b)[39] or unidentified antigen in nerve. The small difference
36
37 between patients with IgG or IgA MGUS (older age and more frequent cranial nerve involvement)
38
39 and patients without support the recommendation of the EFNS/PNS to consider CIDP with MGUS
40
41 not different from idiopathic CIDP.[1]
42
43
44
45
46
47
48

49 The prevalence of other autoimmune disorders (excluding DM) in our cohort (15%) was more than
50
51 three times the estimated prevalence of autoimmune diseases in the general population in
52
53 Europe[29] and is similar to what observed in other diseases, such as myasthenia gravis,[40] celiac
54
55 disease,[41] Graves' disease,[42] and Hashimoto's thyroiditis,[42] all known to be associated with
56
57 an increased risk of other immune-mediated diseases. Laboratory findings suggestive of
58
59 concomitant different immune mediated disorders were also previously reported to be relatively
60

1 common in CIDP.[43] These findings might suggest that CIDP shares common pathogenic
2 mechanisms with other immune disorders. A possible role of the human leukocyte antigen (HLA)
3 phenotype might be reinforced by the recently reported association of DRB1*15 alleles with the
4 presence of anti-NF155 antibodies in patients with CIDP.[44] No HLA data are however available
5 in our population. A more frequent occurrence of cranial nerve involvement was observed in
6 patients with (33%) than without (19%) other autoimmune disorders. The reason for this increased
7 prevalence remains unclear but may either reflect the longer duration of CIDP in these patients or
8 the presence of a possible concomitant pathogenic mechanism related to the underlying
9 autoimmune disorders or just a casual finding as it might be also the case for this association in
10 patients with a concomitant IgG or IgA MGUS.
11
12
13
14
15
16
17
18
19
20
21
22

23
24 A possible association of CIDP with cancer has been previously reported, although there are no
25 epidemiological data consistent with this association.[9] A medical history of solid cancer was
26 present in 9% of our patients, percentage similar to that observed in the general Italian population
27 with the same age.[28] In only 55% of the cases, the diagnosis of cancer preceded the diagnosis of
28 CIDP by a mean of 10 years (mode 8 years, range 1-25), in 29% the diagnosis of CIDP preceded
29 the diagnosis of cancer by a mean of 8.5 years (mode 7 years, range 1-21), while only in 11% of the
30 patients the two diagnoses were made in the same year (table 2). This time discrepancy is not
31 clearly consistent with a possible pathogenetic relationship between CIDP and cancer in most of our
32 patients,[45] as also suggested by the absence of distinguishing demographic or clinical features,
33 including response to therapy, between patients with and without a history of cancer, apart from the
34 older age at symptoms onset in the former group.
35
36
37
38
39
40
41
42
43
44
45
46
47
48

49
50 Some previous studies reported an association between CIDP and lymphoma. [7-9] We found a low
51 prevalence of lymphoma in our patients with CIDP and did not find difference in demographic and
52 clinical features between patients with and without lymphoma. This data and the lapse of time
53 between CIDP and lymphoma (mean 18 years; range 8-39 years) and vice versa (mean 8 year; range
54 7-10 years) do not support a possible paraneoplastic mechanism of the neuropathy. It is not
55
56
57
58
59
60

1 possible, however, to exclude that the immune dysregulation present in lymphoma may somehow
2 influence the appearance of CIDP in these patients.[46]
3
4

5
6 The main limitation of this study is its retrospective nature with information collected from medical
7 charts and by clinical history using a structured questionnaire, without being confirmed by more
8 precise biological or pathogenic indicators. The presence of selection bias cannot be also excluded
9 as, compared to the general population, patients seen in our centers might be more complex cases
10 and, as such, include patients with comorbidities more frequently than expected. It is also possible
11 that this study is only representative of the Italian population and might not be extended to other
12 populations. A non-homogeneous verification of the response to therapy among the different
13 centers might have also influenced the results of this retrospective study. The use of more stringent
14 criteria to define improvement has been also proposed in patients with CIDP.[25] The same
15 approach was however used in each Center for patients with and without comorbidities limiting the
16 possible bias related to our method of assessment. We think however that the results of our study
17 could be the base for future and possibly prospective studies on the association of CIDP with other
18 diseases.
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38

39 **Figure 1. Frequency of comorbidity combinations in 393 CIDP patients**

40 Abbreviations: MGUS = monoclonal gammopathy of undetermined significance

41 **Figure 2. Frequency of comorbidities potentially influencing treatment choice in 393 CIDP patients**

42 **Contributors**

43
44
45
46
47 PED contributed to the conception of the research project, reviewed and commented on the
48 statistical analysis, wrote the first draft of the report, and reviewed the report. DC, FM, RF, CB,
49 MF, LB, SJ, AM, GA, GC, GAM, AC, AMC, MC, AS, GS, ML, GL, TR, GC, EBeghi, GL, LS, ES,
50 EP, ST, MR, SCP, EPV, LG, LL, GM, LP contributed to the conception, organization, and
51 execution of the research project, reviewed and commented on the statistical analysis and the report.
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
EBianchi designed and executed the statistical analysis, contributed to the conception, organization,

1 and execution of the research project, reviewed and commented on the statistical analysis and the
2
3 report. ENO conceived, organized and designed the study, reviewed and commented on the
4
5 statistical analysis, wrote the first draft of the report, reviewed the report.
6

7 **Italian CIDP Database study group**

8
9
10 Pietro Emiliano Doneddu, Giuseppe Liberatore, Francesca Gallia, and Eduardo Nobile-Orazio from
11
12 the Department of Medical Biotechnology and Translational Medicine, Neuromuscular and
13
14 Neuroimmunology Service, Humanitas Clinical and Research Institute, Milan University, Rozzano,
15
16 Milan, Italy; Dario Cocito from Istituti Clinici Scientifici Maugeri, Turin, Italy; Fiore Manganeli,
17
18 Emanuele Spina, Antonietta Topa and Lucio Santoro from the Department of Neuroscience,
19
20 Reproductive Sciences and Odontostomatology, University of Naples 'Federico II', Naples, Italy;
21
22 Daniele Velardo, Stefano Tronci and Raffaella Fazio from the Division of Neuroscience,
23
24 Department of Neurology, Institute of Experimental Neurology (INSPE), San Raffaele Scientific
25
26 Institute, Milan, Italy; Marta Ruiz and Chiara Briani from the Neurology Unit, Department of
27
28 Neuroscience, University of Padua, Padua, Italy; Stefano Cotti Piccinelli, Alice Todeschini and
29
30 Massimiliano Filosto from the Center for Neuromuscular Diseases and Neuropathies, Unit of
31
32 Neurology ASST 'Spedali Civili', University of Brescia, Brescia, Italy; Luana Benedetti from
33
34 Sant'Andrea Hospital, La Spezia, Italy; Elisa Bianchi and Ettore Beghi from IRCCS-Istituto Mario
35
36 Negri, Milan, Italy; Verrengia Elena Pinuccia and Stefano Jann from the Department of
37
38 Neuroscience, Niguarda Ca' Granda Hospital, Milan, Italy; Antonio Toscano, Luca Gentile and
39
40 Anna Mazzeo from the Department of Clinical and Experimental Medicine, Unit of Neurology,
41
42 University of Messina, Messina, Italy; Luca Leonardi and Giovanni Antonini from the Unit of
43
44 Neuromuscular Diseases, Department of Neurology Mental Health and Sensory Organs
45
46 (NESMOS), Faculty of Medicine and Psychology, 'Sapienza' University of Rome, Sant'Andrea
47
48 Hospital, Rome, Italy; Giuseppe Cosentino, Laura Piccolo, Ilaria Callegari and Andrea Cortese
49
50 from the University of Pavia, IRCCS Foundation C. Mondino, Pavia, Italy; Giorgia Mataluni and
51
52 Girolama Alessandra Marfia from the Disimmune Neuropathies Unit, Department of Systems
53
54
55
56
57
58
59
60

1 Medicine, Tor Vergata University of Rome, Rome, Italy; Angelo Maurizio Clerici from the
2
3 Neurology Unit, Circolo & Macchi Foundation Hospital, Insubria University, DBSV, Varese, Italy;
4
5 Federica Scrascia and Marinella Carpo from the ASST Bergamo Ovest-Ospedale Treviglio,
6
7 Treviglio, Italy; Angela Zuppa, Corrado Cabona and Angelo Schenone from the Department of
8
9 Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of
10
11 Genoa and IRCCS AOU San Martino-IST, Genoa, Italy; Erika Schirinzi and Gabriele Siciliano
12
13 from the Neurology Unit, Department of Clinical and Experimental Medicine, University of Pisa,
14
15 Pisa, Italy; Marco Luigetti from Fondazione Policlinico Universitario Agostino Gemelli IRCCS,
16
17 UOC Neurologia, Università Cattolica del Sacro Cuore, Roma, Italy; Patrizia Dacci and Giuseppe
18
19 Lauria from the Unit of Neuroalgology, IRCCS Foundation "Carlo Besta" Neurological Institute,
20
21 Milan, Italy; Tiziana Rosso from the Azienda ULSS. 8 Asolo, Castelfranco Veneto, Italy; Claudia
22
23 Balducci and Guido Cavaletti from the School of Medicine and Surgery and Experimental
24
25 Neurology Unit, University of Milano-Bicocca, Monza, Italy; Mario Sabatelli from Centro Clinico
26
27 NEMO Adulti, Università Cattolica del Sacro Cuore, Roma, Italy; Erdita Peci from the Department
28
29 of Neuroscience, University of Turin, Turin, Italy

35 **Funding**

36
37
38 The study was supported by a Research Grant from Regione Lombardia, Italy, (Grant No.: n/a;
39
40 Progetto Ricerca Indipendente 2012-2013 “Una rete lombarda per lo studio della
41
42 Poliradiculoneuropatia Cronica Infiammatoria Demyelinizzante (CIDP) (RF0180) e delle sue
43
44 varianti per ottimizzare il processo diagnostico e terapeutico alla luce dei costi e del miglioramento
45
46 della qualità della vita”); a Research Grant (2015, Grant No.: n/a;) from the GBS-CIDP Foundation
47
48 International (USA) (“An Italian Multicenter Network for the Diagnosis and Therapy of Chronic
49
50 Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) and of its Variants”) and by
51
52 unrestricted grants (Grant Nos.: n/a) on the same subject from Kedrion Biopharma (Italy), CSL
53
54 Behring (Italy) and Humanitas Clinical and Research Institute (Milan, Italy). The funders had no
55
56 role in study design, data collection and analysis, decision to publish, or preparation of the
57
58 manuscript.
59
60

Competing interests

Pietro Emiliano Doneddu has received travel grants to attend scientific meetings from CSL Behring and Kedrion. Dario Cocito has received honoraria for lecturing from Shire, CSL Behring, and Kedrion and travel grants to attend scientific meeting from Shire, Kedrion, and CSL Behring. Fiore Manganelli reports personal fees for scientific events from CSL Behring and has received travel grants to attend scientific meetings from CSL Behring and Kedrion. Raffaella Fazio has served on scientific advisory boards for CSL Behring and has received travel grants from Kedrion and CSL Behring to attend scientific meeting. Chiara Briani has served on scientific advisory boards for Pfizer, Alnylam, and Akcea, and has received travel grants from Kedrion and CSL Behring to attend scientific meeting. Massimiliano Filosto has served on scientific advisory boards for CSL Behring and has received travel grants from Kedrion, Baxter and CSL Behring to attend scientific meeting. Stefano Jann has received research grants from Grifols, outside this work, and travel grants from Grifols and Kedrion. Anna Mazzeo has received travel grants from Kedrion and CSL Behring to attend scientific meeting. Giuseppe Cosentino has received travel grants to attend scientific meetings from CSL Behring and Kedrion. Andrea Cortese has received travel grants to attend scientific meetings from Kedrion. Marinella Carpo has received travel grants to attend scientific meetings from Kedrion. Marco Luigetti has received travel grants to attend scientific meetings from Kedrion. Guido Cavaletti has received honoraria for lecturing and travel grants to attend scientific meetings from Kedrion. Ettore Beghi reports grants from UCB-Pharma, grants from Shire, grants from EISAI, personal fees from Viropharma, grants from Italian Ministry of Health, grants from Fondazione Borgonovo, grants from Associazione IDIC 15, grants from European Union, outside the submitted work. Giuseppe Liberatore has received travel grants to attend scientific meetings from CSL Behring and Kedrion. Lucio Santoro reports personal fees for scientific events from CSL Behring and has received travel grants to attend scientific meetings from CSL Behring and Kedrion. Erdita Peci has received travel grants to attend scientific meetings from CSL Behring. Eduardo Nobile Orazio reports personal fees for Advisory or Scientific Board from Kedrion, Italy, Baxter, Italy, Novartis, Switzerland, CSL-Behring, Italy, Astellas, the Netherlands, outside the submitted work and travel grants to attend Scientific Meeting from Baxter, Grifols, Kedrion, and Novartis, Italy. The other authors declare no conflict of interest.

Patient consent

Obtained

Ethics approval

The study was approved by the Ethical Committee of each participating Center.

REFERENCES

1. Van den Bergh PY, Hadden RD, Bouche P, et al. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society—First Revision. *Eur J Neurol* 2010;17:356–363.
2. Sharma KR, Cross J, Farronay O, et al. Demyelinating neuropathy in diabetes mellitus. *Arch Neurol* 2002;59:758-765.
3. Chiò A, Plano F, Calvo A, et al. ; Piemonte and Valle D'Aosta Registry for CIDP (PARCIDP). Comorbidity between CIDP and diabetes mellitus: only a matter of chance? *Eur J Neurol* 2009;16:752-754.
4. Laughlin RS, Dyck PJ, Melton LJ 3rd, et al. Incidence and prevalence of CIDP and the association of diabetes mellitus. *Neurology* 2009;73:39-45.
5. Bril V, Blanchette CM, Noone JM, et al. The dilemma of diabetes in chronic inflammatory demyelinating polyneuropathy. *J Diabetes Complications* 2016;30:1401-1407.
6. Rajabally YA, Stettner M, Kieseier BC, et al. CIDP and other inflammatory neuropathies in diabetes - diagnosis and management. *Nat Rev Neurol* 2017;13:599-611.

- 1 7. Viala K, Béhin A, Maisonobe T, et al. Neuropathy in lymphoma: a relationship between the
2 pattern of neuropathy, type of lymphoma and prognosis? *J Neurol Neurosurg Psychiatry*
3 2008;79:778-782.
4
5
6
7
- 8 8. Tomita M, Koike H, Kawagashira Y, et al. Clinicopathological features of neuropathy
9 associated with lymphoma. *Brain* 2013;136:2563-2578.
10
11
12
- 13 9. Rajabally YA, Attarian S. Chronic inflammatory demyelinating polyneuropathy and
14 malignancy: A systematic review. *Muscle Nerve* 2018;57:875-883.
15
16
17
18
- 19 10. Bromberg MB, Feldman EL, Albers JW. Chronic inflammatory demyelinating
20 polyradiculoneuropathy: comparison of patients with and without an associated monoclonal
21 gammopathy. *Neurology* 1992;42:1157-1163.
22
23
24
25
26
- 27 11. Simmons Z, Albers JW, Bromberg MB, et al. Presentation and initial clinical course in
28 patients with chronic inflammatory demyelinating polyradiculoneuropathy: comparison of
29 patients without and with monoclonal gammopathy. *Neurology* 1993;43:2202-2209.
30
31
32
33
34
- 35 12. Simmons Z, Albers JW, Bromberg MB, et al. Long-term follow-up of patients with chronic
36 inflammatory demyelinating polyradiculoneuropathy, without and with monoclonal
37 gammopathy. *Brain* 1995;118:359-368.
38
39
40
41
42
- 43 13. Gorson KC, Allam G, Ropper AH. Chronic inflammatory demyelinating polyneuropathy:
44 clinical features and response to treatment in 67 consecutive patients with and without a
45 monoclonal gammopathy. *Neurology* 1997;48:321-328.
46
47
48
49
- 50 14. Cocito D, Durelli L, Isoardo G. Different clinical, electrophysiological and immunological
51 features of CIDP associated with paraproteinaemia. *Acta Neurol Scand* 2003;108:274-280.
52
53
54
55
- 56 15. Domingos JP, Garrido C, Moreira Silva H, et al. Chronic inflammatory demyelinating
57 polyneuropathy associated with autoimmune hepatitis. *Pediatr Neurol* 2014;51:13-14.
58
59
60

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
16. Mochan A, Anderson D, Modi G. CIDP in a HIV endemic population: A prospective case series from Johannesburg, South Africa. *J Neurol Sci* 2016;363:39-42.
 17. Abraham H, Kuzhively J, Rizvi SW. Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): An Uncommon Manifestation of Systemic Lupus Erythematosus (SLE). *Am J Case Rep* 2017;18:980-983.
 18. Suanprasert N, Taylor BV, Klein CJ, et al. Polyneuropathies and chronic inflammatory demyelinating polyradiculoneuropathy in multiple sclerosis. *Mult Scler Relat Disord* 2019;30:284-290.
 19. Doneddu PE, Cocito D, Manganelli F, et al. Atypical CIDP: diagnostic criteria, progression and treatment response. Data from the Italian CIDP Database. *J Neurol Neurosurg Psychiatry*. Italian CIDP Database study group. *J Neurol Neurosurg Psychiatry* 2019;90:125-132.
 20. Feinstein AR. Pre-therapeutic classification of co-morbidity in chronic disease. *J Chronic Dis* 1970;23:455-468
 21. Istituto Italiano di Statistica. *Annuario Statistico Italiano*, Anno 2018. Roma: ISTAT, 2018.
 22. Vernocchi A, Longhi E, Lippi G, et al. Increased Monoclonal Components: Prevalence in an Italian Population of 44 474 Outpatients Detected by Capillary Electrophoresis. *J Med Biochem* 2016;35:50-54.
 23. Kyle RA, Therneau TM, Rajkumar SV, et al. Prevalence of monoclonal gammopathy of undetermined significance. *N Engl J Med* 2006;354:1362-1369.
 24. Lotan I, Hellman MA, Steiner I. Diagnostic criteria of chronic inflammatory demyelinating polyneuropathy in diabetes mellitus. *Acta Neurol Scand* 2015;132:278-283.
 25. Merkies IS, van Nes SI, Hanna K, et al. Confirming the efficacy of intravenous immunoglobulin in CIDP through minimum clinically important differences: shifting from

- 1 statistical significance to clinical relevance. *J Neurol Neurosurg Psychiatry* 2010;81:1194-
2
3 1199.
4
5 26. Doneddu, PE, Mandia, D, Gentile, F, et al. Home monitoring of maintenance intravenous
6 immunoglobulin therapy in patients with chronic inflammatory neuropathy. *J Peripher Nerv*
7
8 *Syst* 2020;1– 9.
9
10
11
12 27. Torlasco C, Faini A, Makil E, et al. Nation-wide hypertension screening in Italy: data from
13 May Measurements Month 2017-Europe. *Eur Heart J Suppl* 2019;21:66-70.
14
15
16 28. AIRTUM Working Group. Italian cancer figures, report 2014: Prevalence and cure of cancer
17 in Italy. *Epidemiol Prev* 2014;38:1-122.
18
19
20 29. Eaton WW, Rose NR, Kalaydjian A, et al. Epidemiology of autoimmune diseases in
21 Denmark. *J Autoimmun* 2007;29:1-9.
22
23
24 30. Viala K, Maisonobe T, Stojkovic T, et al. A current view of the diagnosis, clinical
25 variants, response to treatment and prognosis of chronic inflammatory demyelinating
26 polyradiculoneuropathy. *J Peripher Nerv Syst* 2010;15:50-56.
27
28
29 31. Wadwekar V, Kalita J, Misra UK. Does the chronic inflammatory demyelinating
30 polyradiculoneuropathy due to secondary cause differ from primary? *Neurol India*
31 2011;59:664-668.
32
33
34 32. Abraham A, Alabdali M, Qrimli M, et al. Treatment Responsiveness in CIDP Patients with
35 Diabetes Is Associated with Higher Degrees of Demyelination. *PLoS One*
36 2015;10:e0139674.
37
38
39 33. Jann S, Bramerio MA, Beretta S, et al. Diagnostic value of sural nerve matrix
40 metalloproteinase-9 in diabetic patients with CIDP. *Neurology* 2003;61:1607–1610
41
42
43
44 34. Mata S, Betti E, Masotti G, et al. Motor nerve damage is associated with anti-ganglioside
45 antibodies in diabetes. *J Peripher Nerv Syst* 2004;9:138–143.
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
35. Dunnigan SK, Ebadi H, Breiner A, et al. The characteristics of chronic inflammatory demyelinating polyneuropathy in patients with and without diabetes--an observational study. *PLoS One* 2014;9:e89344.
36. Bida JP, Kyle RA, Therneau TM, et al. Disease associations with monoclonal gammopathy of undetermined significance: a population-based study of 17,398 patients. *Mayo Clin Proc* 2009;84:685-693.
37. Busby M, Donaghy M. Chronic dysimmune neuropathy. A subclassification based upon the clinical features of 102 patients. *J Neurol* 2003;250:714-724.
38. Nobile-Orazio E, Barbieri S, Baldini L, et al. Peripheral neuropathy in monoclonal gammopathy of undetermined significance: prevalence and immunopathogenetic studies. *Acta Neurol Scand* 1992;85:383-390.
39. Willison HJ, Townson K, Veitch J, et al. Synthetic disialylgalactose immunoadsorbents deplete anti-GQ1b antibodies from autoimmune neuropathy sera. *Brain* 2004;127:680-691.
40. Gilhus NE, Nacu A, Andersen JB, et al. Myasthenia gravis and risks for comorbidity. *Eur J Neurol* 2015;22:17-23.
41. Neuhausen SL, Steele L, Ryan S, et al. Co-occurrence of celiac disease and other autoimmune diseases in celiacs and their first-degree relatives. *J Autoimmun* 2008;31:160-165.
42. Boelaert K, Newby PR, Simmonds MJ, et al. Prevalence and relative risk of other autoimmune diseases in subjects with autoimmune thyroid disease. *Am J Med* 2010;123:1-9.
43. Abraham A, Albulaihe H, Alabdali M, et al. Frequent laboratory abnormalities in CIDP patients. *Muscle Nerve* 2016:862-865.

- 1 44. Martinez-Martinez L, Lleixà MC, Boera-Carnicero G, et al. Anti- NF155 chronic
2
3 inflammatory demyelinating polyradiculoneuropathy strongly associates to HLA-DRB15. *J*
4
5 *Neuroinflammation* 2017;14:224.
6
7
8 45. Graus F, Delattre JY, Antoine JC, et al. Recommended diagnostic criteria for paraneoplastic
9
10 neurological syndromes. *J Neurol Neurosurg Psychiatry* 2004;75:1135-1140.
11
12
13 46. Briani C, Visentin A, Campagnolo M, et al. Peripheral nervous system involvement in
14
15 lymphomas. *J Peripher Nerv Syst* 2019;24:5-18.
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1. Frequency of comorbidity combinations in 393 CIDP patients
Abbreviations: MGUS = monoclonal gammopathy of undetermined significance

254x190mm (600 x 600 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 2. Frequency of comorbidities potentially influencing treatment choice in 393 CIDP patients

254x190mm (600 x 600 DPI)

Supplementary table 1. Statistical comparison of diabetes mellitus prevalence rates

Sex	Age (years)	Number (total)	Observed cases	Observed prevalence * 100	Expected prevalence ¥ * 100	Expected cases ¥	SPR	95% LCL	95% UCL
Females									
	≤ 44	27	3	11.1	0.7	0.2	15.87	4.33	41.02
	45-54	29	2	6.9	2.1	0.6	3.28	0.58	10.34
	55-64	30	4	13.3	5.9	1.8	2.26	0.77	5.17
	65-74	40	4	10.0	11.9	4.8	0.84	0.29	1.92
	75-79	6	1	16.7	15.3	0.9	1.09	0.06	5.17
	≥ 80	0	0	-	21.9	0.0	-	-	-
	All	141	14	9.9	5.8	8.2	1.70	1.03	2.65
Males									
	≤ 44	42	1	2.4	0.6	0.3	3.97	0.20	18.82
	45-54	41	7	17.1	3.5	1.4	4.88	2.29	9.16
	55-64	64	10	15.6	8.8	5.6	1.78	0.96	3.01
	65-74	59	13	22.0	15.2	9.0	1.45	0.86	2.30
	75-79	27	6	22.2	20.4	5.5	1.09	0.47	2.15
	≥ 80	19	5	26.3	19.4	3.7	1.36	0.53	2.85
	All	252	42	16.7	10.1	25.5	1.65	1.25	2.13
Total									
	≤ 44	69	4	5.8	0.6	0.4	9.07	3.10	20.76
	45-54	70	9	12.9	2.9	2.0	4.40	2.30	7.68
	55-64	94	14	14.9	7.9	7.4	1.89	1.14	2.96
	65-74	99	17	17.2	13.9	13.7	1.24	0.79	1.86
	75-79	33	7	21.2	19.5	6.4	1.09	0.51	2.05
	≥ 80	28	5	17.9	13.2	3.7	1.36	0.53	2.85
	All	393	56	14.2	8.6	33.7	1.66	1.31	2.07

SPR= standardised prevalence ratio

¥ refers to values derived using ISTAT (2018) data

Supplementary table 2. Statistical comparison of MGUS prevalence rates

Sex	Age (years)	Number total	Observed cases	Observed prevalence * 100	Expected prevalence ¥ * 100	Expected cases ¥	SPR	95% LCL	95% UCL
Females									
	50-59	27	3	11.1	1.4	0.4	7.94	2.16	20.51
	60-69	37	4	10.8	2.3	0.9	4.70	1.61	10.76
	70-79	24	8	33.3	3.8	0.9	8.77	4.36	15.83
	≥ 80	9	1	11.1	6.0	0.5	1.85	0.09	8.78
	All	97	16	16.5	2.8	2.7	5.97	3.74	9.06
Males									
	50-59	55	4	7.3	2.0	1.1	3.64	1.24	8.32
	60-69	65	8	12.3	3.7	2.4	3.33	1.66	6.00
	70-79	57	13	22.8	5.6	3.2	4.07	2.41	6.48
	≥ 80	19	3	15.8	8.3	1.6	1.90	0.52	4.92
	All	196	28	14.3	4.2	8.3	3.38	2.41	4.64
Total									
	50-59	82	7	8.5	1.8	1.5	4.74	2.22	8.90
	60-69	102	12	11.8	3.2	3.3	3.69	2.13	5.97
	70-79	81	21	25.9	5.1	4.1	5.12	3.43	7.37
	≥ 80	28	4	14.3	7.6	2.1	1.89	0.65	4.32
	All	293	44	15.0	3.7	11.0	4.02	3.07	5.16

SPR= standardised prevalence ratio

¥ refers to values derived using Kyle *et al.* (2006) data

Supplementary table 3. Statistical comparison of MGUS prevalence rates

Sex	Age (years)	Number (total)	Observed cases	Observed prevalence * 100	Expected prevalence ¥ * 100	Expected cases ¥	SPR	95% LCL	95% UCL
Females									
	51-60	29	3	10.3	3.7	1.1	2.77	0.75	7.15
	61-70	36	5	13.9	4.7	1.7	2.93	1.15	6.16
	71-80	22	7	31.8	6.0	1.3	5.30	2.49	9.96
	81-90	8	1	12.5	7.1	0.6	1.76	0.09	8.36
	All	95	16	16.8	4.9	4.7	3.42	2.15	5.19
Males									
	51-60	58	4	6.9	4.1	2.4	1.69	0.58	3.86
	61-70	66	9	13.6	6.8	4.5	2.00	1.04	3.49
	71-80	53	12	22.6	10.3	5.4	2.20	1.27	3.57
	81-90	15	2	13.3	12.1	1.8	1.10	0.20	3.47
	All	192	27	14.1	7.4	14.1	1.91	1.35	2.63
Total									
	51-60	87	7	8.0	4.0	3.5	2.02	0.95	3.80
	61-70	102	14	13.7	6.1	6.2	2.26	1.36	3.53
	71-80	75	19	25.3	9.0	6.8	2.81	1.84	4.12
	81-90	23	3	13.0	10.4	2.4	1.26	0.34	3.25
	All	287	43	15.0	6.6	18.8	2.29	1.74	2.95

SPR= standardised prevalence ratio

¥ refers to values derived using Vernocchi *et al.* (2016) data